drugset / Trial / NCT00215241

Risperidone Augmentation for PTSD

NCT00215241

Phase 2/3 Completed 80 enrolled Duke University Janssen Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to (1) compare the response of civilians with Posttraumatic Stress Disorder(PTSD) currently receiving sertraline without an optimal response to risperidone augmentation vs. placebo, and (2) to evaluate the tolerability of risperidone augmentation, and (3) to identifiy predictors of response to risperidone augmentation. the hypothesis is that risperidone augmentation of sertraline treatment of PTSD is safe and effective.

Timeline

Start
2004-04
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 3 mg
Background Sertraline Small molecule 200 mg